icon-account icon-glass
FREE Podcast Series with Medical Advisor Dr. Bill Code
Connect

Cymbalta WITHDRAWAL

Cymbalta Withdrawal and Tapering Help

Call us about our Cymbalta taper program   

Have you tried to come off Cymbalta only to reinstate due to the Cymbalta Withdrawal symptoms?  Have you tried a slow Cymbalta Taper and yet the symptoms were overwhelming?  We know you need relief and our nonprofit has been helping people for 15 years, in 78 countries, to come off Cymbalta with a holistic approach to controlling the Cymbalta Withdrawal.  We guide each client on proper taper rates and potential Cymbalta Interactions with herbs and over-the-counter items and we provide a Cymbalta Withdrawal plan that is right for you so you can do a slow Cymbalta Taper at home. Our nonprofit has a highly skilled team that is here to help you get off Cymbalta.  Contact us today for a FREE consultation.

read more...

SUCCESSFUL CHOICES YOU CAN MAKE RIGHT NOW

START OUR CYMBALTA WITHDRAWAL PROGRAM

LEARN MORE ABOUT OUR IN-HOME WITHDRAWAL PROGRAM

LIVE CHAT

EMAIL

TALK TO A REAL PERSON 866-605-2333 (toll-free)

REACH OUT FORM

"Contacting Point of Return was the best decision I made in my adult life.  - Glenn (Cymbalta Withdrawal Success Story)

Enter Discount Code  ADFree for FREE Ground Shipping on your Withdrawal Program  *USA & Canada Only

HOW IT WORKS:

Start Our Duloxetine withdrawal program  

Our Cymbalta weaning program is a slow taper that allows you to safely step down from Cymbalta under the guidance of our Prescription Experts, your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean Cymbalta until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help minimize Cymbalta withdrawal symptoms to improve mental and physical well-being.

Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Cymbalta Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; and interactions. Don't Wean Cymbalta alone, work with our Prescription Drug Experts.

Imagine being Free of Cymbalta Addiction 

- Proven Withdrawal Program completed In-Home with Expert Guidance

- Slowly Wean off Cymbalta

- All-Natural Nutraceuticals to help Ease Cymbalta Withdrawal Symptoms

- Professional information on interactions

- Free Mentoring on our 24/7 private Discussion Board

- Free Assessment Upon Starting our Program (a $400 value)

      PROVEN RESULTS

      SIMPLE - NATURAL - SAFE - EFFECTIVE

      CYMBALTA WITHDRAWAL SUCCESS STORIES

      Lois - Cymbalta Withdrawal

      I can't give you guys enough praise for starting this withdrawal program and for putting in all your effort to save people who need help so desperately. More...

      Lois (Cymbalta Withdrawal Success Story)

      Luis - Cymbalta withdrawal success

      I just want to say hello to all the staff at POINT OF RETURN. I am doing fine. I am now 2-1/2 years without drugs. Without all your support it would be impossible to get off those drugs. More...

      Luis (Cymbalta Withdrawal Success Story)

      Pamela - Cymbalta withdrawal

      I am proud to say I have been completely Cymbalta free. It works. The program continues to work. And, if I have a bad moment, the Point of Return team is an email or phone call away.  more...

      Pamela (Cymbalta Withdrawal Success Story)

      I’ve been off the medication for a little over a year and I will be forever grateful for the support and knowledge the Point of Return staff gave me. Contacting them was the best decision I made in my adult life."

      Glenn (Cymbalta Withdrawal Success Story)

      REACH OUT

      Message sent, thanks!

      Cymbalta Resource Center

      CYMBALTA WITHDRAWAL SYMPTOMS, SIDE EFFECTS AND ADVERSE REACTIONS ( link | pdf )


      CYMBALTA HISTORY AND INFO  ( link | pdf )


      CYMBALTA REFERENCES AND FDA INFO ( link | pdf )

      Cymbalta Info and History

      Cymbalta (Duloxetine) is a SNRI (Serotonin-Norepinephrine Reuptake Inhibitor) created by Eli Lilly in 1986 and after approval by the FDA in 2008 Cymbalta was prescribed for major depression, generalized anxiety, fibromyalgia and neuropathic pain.  The severity of withdrawal symptoms from Cymbalta was bad enough to warrant its own diagnosis ‘Cymbalta Discontinuation Syndrome’ and an FDA advisory committee report states, “Much anecdotal evidence has accumulated documenting the injury, distress and life management impacts caused by discontinuation of Cymbalta. The effects of discontinuation can be severe and extend for weeks or even months.” 

      Duloxetine did not receive US approval for urinary incontinence due to the concerns over liver toxicity and suicidal events. The FDA experts concluded that Cymbalta could potentially cause hepatoxicity (liver damage) and QTc Interval Prolongation (interruption of the heart’s electrical cycle) but followup studies indicated no heart related concerns.

      10-20% of patients state nausea, insomnia, dizziness and fatigue as the primary side effects, but dry mouth, sexual dysfunction and headaches were also commonly reported.

      The prescribing information for Cymbalta states, “A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.”

      Cymbalta Withdrawal Symptoms, Side Effects, Adverse Reactions

      CYMBALTA WITHDRAWAL SYMPTOMS MAY INCLUDE:

      aggression, anxiety, balance issues , blurred vision, brain zaps, concentration impairment, constipation, crying spells, depersonalization, diarrhea, dizziness. electric shock sensations, fatigue, flatulence, flu-like symptoms, hallucinations, hostility, highly emotional, indigestion, irritability, impaired speech, insomnia, jumpy nerves, lack of coordination, lethargy, migraine headaches / increased headaches, nausea, nervousness, over-reacting to situations, paranoia, repetitive thoughts or songs, sensory & sleep disturbances, severe internal restlessness (akathisia), stomach cramps, tremors, tinnitus (ear ringing or buzzing), tingling sensations, troubling thoughts, visual hallucinations / illusions, vivid dreams, speech or visual changes, worsened depression 

      CYMBALTA SIDE EFFECTS MAY INCLUDE:

      allergy, daytime drowsiness, dizziness, drugged feeling, headache, indigestion, nausea, difficulty with coordination, memory loss, tolerance, dependency, changes in behavior and thinking, more outgoing, strange behavior, agitation, worsening of depression, suicidal thoughts, abdominal pain, abnormal dreams, abnormal vision, amnesia, anxiety, arthritis, back pain, bronchitis, burning sensation, chest pain, confusion, constipation, coughing, daytime sleeping, decreased mental alertness, depression, diarrhea, difficulty breathing, difficulty concentrating, difficulty swallowing, diminished sensitivity to touch, dizziness on standing, double vision, dry mouth, emotional instability, exaggerated feeling of well-being, eye irritation, falling, fatigue, fever, flu-like symptoms, gas, general discomfort, hallucination, hiccup, high blood pressure, high blood sugar, increased sweating, infection, insomnia, itching, joint pain, lack of bladder control, lack of coordination, lethargy, light-headedness, loss of appetite, menstrual disorder, migraine, muscle pain, nasal inflammation, nervousness, numbness, paleness, prickling or tingling sensation, rapid heartbeat, rash, ringing in the ears, sinus inflammation, sleep disorder, speech difficulties, swelling due to fluid retention, taste abnormalities, throat inflammation, throbbing heartbeat, tremor, unconsciousness, upper respiratory infection, urinary tract infection, vertigo, vomiting, weakness, abnormal tears or tearing, abscess, acne, aggravation of allergies, aggravation of high blood pressure, aggression, allergic reaction, altered production of saliva, anemia, belching, blisters, blood clot in lung, boils, breast pain, breast problems, breast tumors, bruising, chill with high temperature followed by heat and perspiration, decreased sex drive, delusion, difficulty urinating, excessive urine production, eye pain, facial swelling due to fluid retention, fainting, false perceptions, feeling intoxicated, feeling strange, flushing, frequent urination, glaucoma, gout, heart attack, hemorrhoids, herpes infection, high cholesterol, hives, hot flashes, impotence, inability to urinate, increased appetite, increased tolerance to the drug, intestinal blockage, irregular heartbeat, joint degeneration, kidney failure, kidney pain, laryngitis, leg cramps, loss of reality, low blood pressure, mental deterioration, muscle spasms in arms and legs, muscle weakness, nosebleed, pain, painful urination, panic attacks, paralysis, pneumonia, poor circulation, rectal bleeding, rigidity, sciatica (lower back pain), sensation of seeing flashes of lights or sparks, sensitivity to light, sleepwalking, speech difficulties, swelling of the eye, thinking abnormalities, thirst, tooth decay, uncontrolled leg movements, urge to go to the bathroom, varicose veins, weight loss, and yawning

      CYMBALTA ADVERSE REACTIONS MAY INCLUDE: per PDR

      Severe: myocardial infarction, visual impairment, suicidal ideation , GI bleeding, peptic ulcer, seizures, pancreatitis, Incidence, Stevens-Johnson syndrome , anaphylactoid reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), erythema multiforme, angioedema, vasculitis, hepatic failure, cardiomyopathy, hypertensive crisis , ocular hypertension, SIADH , hyperkalemia, serotonin syndrome, neonatal abstinence syndrome

      Moderate: constipation, impotence (erectile dysfunction), ejaculation dysfunction , blurred vision, palpitations, elevated hepatic enzymes , myoclonia, confusion, dyskinesia, gastritis, stomatitis, teeth grinding (bruxism), dehydration, contact dermatitis, erythema, hot flashes, dysuria, sinus tachycardia, hypotension, orthostatic hypotension, hypothyroidism, dysarthria, mania, withdrawal, hyperglycemia, trismus, hallucinations, colitis, urinary retention, hepatomegaly, hyperbilirubinemia, hepatitis, jaundice, cholestasis, supraventricular tachycardia (SVT), hypertension, impulse control symptoms, hostility, akathisia, depression, hyponatremia, hematoma, platelet dysfunction, bleeding, galactorrhea, hyperprolactinemia, hypokalemia, hypercholesterolemia

      Mild: nausea, headache, xerostomia, weight loss, abdominal pain, drowsiness, asthenia, fatigue , insomnia, dizziness, anorexia, vomiting, diarrhea, hyperhidrosis, agitation, restlessness, musculoskeletal pain, myalgia, pharyngitis, infection, back pain, tremor, anxiety, flushing , libido decrease, cough, nightmares, yawning, hypoesthesia, dyspepsia, orgasm dysfunction, influenza, irritability, tinnitus, otalgia , malaise, halitosis, eructation, polydipsia, night sweats, photosensitivity, polyuria, nocturia , increased urinary frequency, syncope, diplopia, xerophthalmia, menstrual irregularity, laryngitis, ecchymosis, dysgeusia, vertigo, lethargy, flatulence, weight gain, pruritus, chills, muscle cramps, restless legs syndrome (RLS), paresthesias, rash, urticaria, mydriasis, epistaxis, petechiae

      CYMBALTA BOXED WARNINGS: per PDR

      Children, growth inhibition, suicidal ideation

      Duloxetine is not recommended for use in children less than 7 years of age; safety and efficacy have not been established. Duloxetine is FDA-approved for use in children and adolescents 7 years and older with generalized anxiety disorder (GAD); efficacy for major depressive disorder (MDD) was not established in two 10-week controlled trials with 800 pediatric patients (7 years and older). In October 2004, the FDA directed manufacturers of all antidepressants to add a boxed warning to their product labels detailing the risk of suicide in pediatric patients. The risk of suicidality for these drugs was identified in a pooled analysis of 24 placebo-controlled trials (n = 4,400) lasting up to 16 weeks in pediatric patients with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants. The average risk of such events on drug was 4% and 2% for placebo; however, no suicides occurred in these trials. Pooled analysis of short-term clinical trials during early phase treatment with antidepressants in young adults (18 to 24 years) also showed an increased risk of suicidal thinking and behavior. The clinical need for an antidepressant in pediatrics or young adults for any use must be weighed against the risk of increased suicidality; patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior, particularly within the first few months of starting therapy or during dose changes. It is unknown if the suicidality risk in children or young adults extends to longer-term therapy. The possibility of a suicide attempt is inherent in patients with depressive symptoms, whether these occur in primary depression or in association with another primary disorder. All patients with a history of suicidal ideation or behaviors and those with a prominence of suicidal ideation prior to treatment should be closely monitored during treatment with duloxetine. In patients who exhibit worsening of depression or suicidality, a decision should be made to change or discontinue treatment. If discontinuing, the medication should be tapered as rapidly as possible, but with recognition that abrupt discontinuation can also cause adverse symptoms. All antidepressants should be prescribed in the smallest quantity consistent with good patient management to reduce the risk of overdose. The potential for growth inhibition in pediatric patients should be monitored during duloxetine therapy. Monitor height and weight periodically while the patient is receiving duloxetine. Data are inadequate to determine whether the chronic use of SNRIs causes long-term growth inhibition; however, decreased weight gain has been observed in children and adolescents receiving duloxetine.

      Cymbalta References and Information

      According to the FDA and Eli Lilly.

      Discontinuing Cymbalta

      Symptoms associated with discontinuation of Cymbalta and other SSRIs and SNRIs have been reported (see PRECAUTIONS). Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.

      Per the FDA:

      If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that discontinuation can be associated with certain symptoms [see Dosage and Administration (2.7) and Warnings and Precautions (5.7) for descriptions of the risks of discontinuation of CYMBALTA].

      Discontinuation: May result in symptoms, including dizziness, headache, nausea, diarrhea, paresthesia, irritability, vomiting, insomnia, anxiety, hyperhidrosis, and fatigue (5.7)

      Activation of mania or hypomania has occurred (5.8)

      Angle-Closure Glaucoma: Angle-closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants. (5.9)

      Seizures: Prescribe with care in patients with a history of seizure disorder (5.10)

      Blood Pressure: Monitor blood pressure prior to initiating treatment and periodically throughout treatment (5.11)

      Inhibitors of CYP1A2 or Thioridazine: Should not administer with CYMBALTA (5.12)

      Hyponatremia: Cases of hyponatremia have been reported (5.13)

      Glucose Control in Diabetes: In diabetic peripheral neuropathic pain patients, small increases in fasting blood glucose, and HbA1c have been observed (5.14)

      Conditions that Slow Gastric Emptying: Use cautiously in these patients (5.14)

      Urinary Hesitation and Retention 

       

      DISCLAIMER:

      *While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.

      *The statements on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.

      * Testimonial results may vary person to person.

      *The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized with your physician to help you with your drug withdrawal process and with his or her consent.

      *Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support. More..